advisorsecurities master

MTVAMetaVia Inc. Common Stock

CSNasdaq (XNAS)·USD

Identity

Security key
18869
Ticker
MTVA
Type
CSCommon Stock
Exchange
Nasdaq(XNAS)
Venue group
NASDAQ
Operating MIC
XNAS
Market
stocks
Locale
us
Currency
USD
Listed
2016-08-04
Round lot
100
Active
Yes
Last seen in a load
2026-08-14 20:49
Vendor updated
2026-08-13 06:09
Ticker root / suffix
MTVA

Detail

Enriched 2026-08-14 20:47

Market cap
$7,591,623.9
Shares outstanding (class)
5,164,370
Shares outstanding (weighted)
5,164,370
SIC
2834 PHARMACEUTICAL PREPARATIONS
Employees
8
Location
CAMBRIDGE, MA
Description

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.

Market cap and share counts drift.

Funds holding this security

Identifiers

Classification

Fund data